Is pembrolizumab monotherapy the optimal treatment for elderly patients with PD-L1 positive advanced non-small cell lung cancer?

被引：1
|
作者：
Mienko, Fiona [1 ]
Halmos, Balazs [1 ]
Cheng, Haiying [1 ]
机构：
[1] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Med Oncol, Bronx, NY 10467 USA
来源：
ANNALS OF TRANSLATIONAL MEDICINE | 2020年 / 8卷 / 12期
关键词：
PERFORMANCE STATUS; NIVOLUMAB; DOCETAXEL; EFFICACY;
D O I：
10.21037/atm.2020.02.68
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer
    Thu Oanh Dang
    Ogunniyi, Adebayo
    Barbee, Meagan S.
    Drilon, Alexander
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (01) : 13 - 20
  • [2] Elderly patients and PD-L1-positive advanced non-small cell lung cancer: is pembrolizumab monotherapy effective and safe?
    Gridelli, Cesare
    Sgambato, Assunta
    ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7
  • [3] REAL WORLD OUTCOMES OF FIRST LINE PEMBROLIZUMAB MONOTHERAPY FOR ADVANCED PD-L1 POSITIVE NON-SMALL CELL LUNG CANCER
    Chu, R.
    Vegas, A.
    Gorry, C.
    Power, D.
    VALUE IN HEALTH, 2022, 25 (01) : S253 - S253
  • [4] Pembrolizumab monotherapy for PD-L1 ≥50% non-small cell lung cancer, undisputed first choice?
    Theelen, Willemijn S. M. E.
    Baas, Paul
    ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7
  • [5] Pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for PD-L1-positive advanced non-small cell lung cancer in the real world
    Sugisaka, J.
    Sugawara, S.
    Toi, Y.
    Ogasawara, T.
    Aso, M.
    Tsurumi, K.
    Ono, K.
    Shimizu, H.
    Domeki, Y.
    Aiba, T.
    Kawana, S.
    Saito, R.
    Terayama, K.
    Kawashima, Y.
    Nakamura, A.
    Yamanda, S.
    Kimura, Y.
    Honda, Y.
    ANNALS OF ONCOLOGY, 2019, 30
  • [6] Efficacy of Pembrolizumab Monotherapy in Patients With or Without Brain Metastases From Advanced Non-Small Cell Lung Cancer With a PD-L1 Expression ≥50%
    Metro, Giulio
    Banna, Giuseppe Luigi
    Signorelli, Diego
    Gili, Alessio
    Galetta, Domenico
    Galli, Giulia
    Economopoulou, Panagiota
    Roila, Fausto
    Friedlaender, Alex
    Camerini, Andrea
    Christopoulou, Athina
    Cantale, Ornella
    De Toma, Alessandro
    Pizzutilo, Pamela
    Jimenez, Beatriz
    Collazo-Lorduy, Ana
    Calles, Antonio
    Baxevanos, Panagiotis
    Linardou, Helena
    Kosmidis, Paris
    Giannarelli, Diana
    Mountzios, Giannis
    Addeo, Alfredo
    JOURNAL OF IMMUNOTHERAPY, 2020, 43 (09) : 299 - 306
  • [7] Advanced non-small cell lung cancer with PD-L1≥50%: Pembrolizumab alone or combined with chemotherapy
    Han, B.
    Han, B.
    Zhang, B.
    Hu, M.
    Wang, Y.
    Yang, Z.
    Zhang, W.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S758 - S759
  • [8] COST EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB MONOTHERAPY IN ADVANCED PD-L1 ≥50% NON-SMALL CELL LUNG CANCER (NSCLC) IN THE IRISH SETTING
    Chu, R.
    Vegas, A.
    Gorry, C.
    Power, D.
    VALUE IN HEALTH, 2022, 25 (01) : S61 - S61
  • [9] Efficacy and safety of PD-1/PD-L1 inhibitors in elderly patients with advanced non-small cell lung cancer
    Li, Li
    Xu, Chunhua
    Wang, Wei
    Zhang, Qian
    CLINICAL RESPIRATORY JOURNAL, 2024, 18 (05):
  • [10] PD-L1 expression for advanced non-small cell lung cancer patients with cancer cachexia
    Morimoto, Kenji
    Yamada, Tadaaki
    CANCER SCIENCE, 2023, 114 : 1410 - 1410
12345